Clinical Practice Guideline: Hepatitis B Screening and Prophylaxis for Patients Requiring Immunosuppression

Brief Description: This guideline provides guidance in the correct screening and management of patients prior to immunosuppression. Liver failure rates in patients with undetected hepatitis B Virus (HBV) receiving immunosuppressing cancer therapies is as high as 14%. Screening and treating appropriately can drastically reduce the risk of HBV reactivation and liver failure. Vaccinate all patients who do not have chronic HBV and do not have immunity. This does not need to delay their planned treatment. 


• Patients with prior exposure to HBV are at risk for disease reactivation based on serologies